Just a moment, the page is loading...

*EISAI-E7080-G000-205 Ph1b




An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
lenvatinib
E7080-G000-205 Ph1b
NCT01136733
EU CTR 2010-019484-10
Metastatic Renal Cell Carcinoma
Phase 1
 
No restrictions. Note: The Protocol and Statistical Analysis Plan are part of the phase 2 study documents.
November 2017